Stiff-person syndrome refers to the nervous system losing some control over muscle relaxation, causing stiffness and painful spasms. The main symptoms include progressive muscle stiffness, painful spasms, slow or difficult walking, falls, and increased sensitivity to sudden sounds or touch. SPS is usually linked to an autoimmune reaction involving the central nervous system, with anti-GAD65 antibodies found in many patients, although other forms can involve different antibodies.

Treatment may include physiotherapy, medicines that calm muscle activity, immunotherapy such as intravenous immunoglobulin (IVIG), and other specialist treatments for severe disease. Diazepam is one medicine used to reduce muscle stiffness and spasms because it strengthens the effects of GABA, an inhibitory chemical messenger in the nervous system. In the UK, diazepam is prescription-only and is normally obtained through a registered prescriber and pharmacy.

What Is Stiff Person Syndrome or SPS?

Stiff-person syndrome, also known as stiff-man syndrome or SPS, is an autoimmune neurological disorder that is uncommon and causes progressive muscle stiffness, painful spasms, and abnormal nervous-system excitability.

According to research, SPS affects roughly 1-2 people per million, although newer epidemiological work suggests the condition may be more common than earlier estimates indicated. Classic SPS accounts for around 70–80% of cases within the recognised SPS spectrum.

According to Dr Scott Newsome, director of the Stiff Person Syndrome Center at Johns Hopkins, SPS is an autoimmune neurological condition in which the immune system mistakenly attacks the nervous system, leading to severe spasms, pain, walking difficulties and other symptoms. His explanation is useful because SPS can look very different from one person to another, especially during the early stages.

SPS involves the central nervous system, particularly the pathways that normally keep muscle activity under control. GABA is one of the brain’s main inhibitory chemical messengers. In SPS, autoimmune activity can interfere with GABA-related signalling, leaving motor neurons unusually excitable. Muscles can then remain tense or react excessively to movement, sudden sounds, touch, emotional stress, or other triggers. Anti-GAD65 antibodies are strongly associated with many cases, although not every person with SPS has them.

The condition is considered a progressive condition, but its course varies considerably. Some people develop mainly stiffness and spasms in the trunk and legs, while others develop symptoms affecting one limb or additional neurological systems. Current classifications include classic SPS, partial SPS types, and progressive encephalomyelitis with rigidity and myoclonus (PERM).

The first recognised medical description came in 1956, when neurologists like Frederick Moersch and well-known Henry Woltman reported 14 patients with progressive, fluctuating muscle rigidity and spasms. They originally called it stiff-man syndrome. The name was later changed to stiff-person syndrome as doctors recognised that the disorder affects people of different sexes.

What Is the History of Stiff Person Syndrome?

The history of stiff-person syndrome started long before doctors gave the disorder its modern name. Ancient medical writings described people with severe muscle rigidity and spasms, although those observations could not distinguish SPS from conditions such as tetanus, seizures, spasticity, or other neurological disorders. The important point is that muscle rigidity itself was recognised centuries before its underlying causes were understood.

A significant milestone in the wider history of abnormal muscle stiffness came in the 19th century. British surgeon Dr William John Little described 47 children with what he called spastic rigidity in 1862. His observations helped establish the medical description of what is now recognised as the spastic form of cerebral palsy. This was not SPS, but it helped physicians develop a more precise language for distinguishing different patterns of abnormal muscle tone.

The history of SPS itself changed in 1956, when Moersch and Woltman published their report of 14 patients. They described progressive stiffness involving the trunk and limbs, painful spasms, and difficulty walking. Electromyography also helped show that the muscles were being activated abnormally rather than simply becoming mechanically stiff.

During the following decades, researchers began to understand that SPS was not simply a muscle disorder. Abnormal spinal reflex control and impaired inhibitory signalling became important parts of the explanation. Later research identified an autoimmune component, including the association between SPS and GAD antibodies reported in the late 1980s. This shifted SPS from an unexplained movement disorder towards its current understanding as a neuroimmunological disease.

Treatment has also changed considerably. Early management focused mainly on controlling stiffness and spasms with medicines that affect inhibitory nerve signalling, particularly benzodiazepines such as diazepam. Modern care can also include immunotherapies such as IVIG, corticosteroids in selected cases, and other immune-directed treatments. Severe or treatment-resistant cases may require specialist approaches.

It is important not to confuse the treatment history of spasticity with the history of SPS. Procedures such as neurotomy and dorsal rhizotomy have been used for selected forms of severe spasticity, particularly when abnormal muscle tone results from conditions such as cerebral palsy or spinal cord injury. They are not standard historical treatments for stiff-person syndrome. The different types of stiff-person syndrome, including classic SPS, partial variants, stiff-limb presentations and PERM, have instead emerged from attempts to describe how the autoimmune neurological disorder can affect different parts of the nervous system.

The history therefore tells an important story: SPS was once recognised mainly by what doctors could see — stiffness and spasms. Modern medicine now looks deeper, examining abnormal GABAergic signalling, autoantibodies, electrophysiology, and the wider immune system to understand why those symptoms occur.

What Are the Symptoms of Stiff Person Syndrome?

The symptoms of stiff-person syndrome include muscle rigidity, painful muscle spasms, balance and walking problems, sensitivity to noise and stress, chronic pain, and anxiety or emotional distress. Symptoms can develop gradually and vary between people, so early signs may be mistaken for other neurological or musculoskeletal conditions.

The symptoms of stiff-person syndrome are listed below. Each symptom has a different biological basis, although several are linked to the same problem: abnormal control of muscle activity by the central nervous system.

Why Can These Symptoms Be Misunderstood?

Some stiff-person syndrome symptoms overlap with other neurological, autoimmune, and musculoskeletal conditions. Muscle stiffness, pain, restricted movement, and difficulty walking can have many possible causes, so SPS may take time to recognise. Its rarity also makes diagnosis more challenging.

SPS can even be misunderstood as scleroderma, particularly when a person has prominent muscle or joint stiffness. The two conditions are fundamentally different. Scleroderma is an autoimmune connective-tissue disease that can cause skin thickening and tightening, whereas SPS primarily affects neurological control of muscle activity.

The pattern of symptoms can provide important clues. Repeated spasms triggered by sudden sounds or touch, progressive rigidity, exaggerated startle responses, and characteristic abnormalities on electromyography can point clinicians towards SPS. These signs are assessed alongside the person’s medical history, neurological examination, antibody testing, and other investigations rather than relying on one symptom alone.

What Is the Difference Between Stiff Person Syndrome and Scleroderma?

The difference between stiff-person syndrome and scleroderma is that SPS is primarily a neurological autoimmune disorder affecting muscle control, while scleroderma is a connective-tissue disease that causes fibrosis and hardening of the skin and sometimes internal organs.

The key science-based difference is where the disease mainly acts: SPS involves abnormal inhibitory signalling within the central nervous system, often associated with antibodies such as anti-GAD65, while scleroderma involves immune-system dysfunction that promotes excess collagen production and fibrosis in connective tissues. Scleroderma can also affect blood vessels and organs such as the lungs, kidneys, heart, and digestive system.

The names can confuse because both conditions may involve stiffness, pain, and difficulty moving. The underlying mechanisms are very different, though. SPS causes muscles to remain abnormally active because normal inhibitory control is disrupted. Scleroderma produces physical changes in connective tissue that can make the skin and surrounding tissues tight or hardened.

SPS is sometimes misunderstood as ALS (amyotrophic lateral sclerosis) as well. Both can cause difficulty moving and other neurological problems, but they involve different disease processes and require different diagnostic approaches.

What Is the Difference Between Stiff Person Syndrome and ALS?

The difference between stiff-person syndrome and ALS is that SPS mainly causes abnormal muscle stiffness and spasms through impaired inhibitory signalling, while ALS progressively damages motor neurons responsible for voluntary muscle movement.

The key science-based difference is the type of neurological dysfunction. In SPS, autoimmune activity can interfere with inhibitory GABA-related pathways, producing persistent muscle rigidity, painful spasms, and exaggerated responses to stimuli. ALS causes progressive degeneration of upper and lower motor neurons, leading to muscle weakness, wasting, twitching, speech difficulties, swallowing problems, and eventually respiratory muscle weakness.

The early signs can sometimes overlap. A person with either condition may notice difficulty walking or changes in movement, but the pattern is different. Stiffness and stimulus-triggered spasms are particularly important clues in SPS, while progressive weakness, muscle wasting, fasciculations, or loss of motor function can point towards ALS.

Understanding these differences matters because neither condition should be diagnosed from symptoms alone. A neurologist may use the medical history, neurological examination, electromyography, blood tests, imaging, and other investigations to determine the most likely cause.

What Are the Early Warning Signs of SPS?

The early signs of stiff-person syndrome are listed below. They may appear gradually and can initially resemble other neurological or musculoskeletal problems.

• Mild stiffness: Early muscle stiffness may appear in the lower back, abdomen, hips, or legs before becoming more widespread.
• Unexpected spasms: Sudden involuntary contractions may occur without warning or after noise, touch, movement, or emotional stress.
• Posture changes: Increasing trunk and limb rigidity can gradually alter posture as muscles remain contracted during ordinary movement.
• Fear of walking or falling: Repeated spasms, instability, and previous falls can make a person increasingly afraid of walking independently.
• Difficulty walking: Persistent muscle rigidity can restrict normal joint movement and produce an increasingly abnormal gait.
• Increased startle response: Ordinary sounds or unexpected physical contact may produce unusually strong muscle contractions or spasms.
• Muscle pain: Persistent contraction and repeated spasms can place continuous stress on muscles, producing local or widespread pain.
• Movement-related anxiety: Anticipating a painful spasm can cause a person to avoid certain movements or situations that previously felt safe.

These early features do not by themselves confirm SPS. The causes of stiff-person syndrome are usually linked to autoimmune activity affecting the nervous system, and proper diagnosis requires assessment by a qualified clinician.

What Are the Causes of Stiff Person Syndrome?

The causes of stiff-person syndrome include autoimmune dysfunction, GAD-related autoantibodies, abnormal inhibitory signalling in the nervous system, associated autoimmune diseases, and type 1 diabetes.

The causes of stiff-person syndrome are listed below. SPS does not usually result from a single cause. Current evidence points towards an autoimmune process that interferes with inhibitory pathways in the central nervous system, although the exact reason why the immune system starts this response remains uncertain.

How Do These Causes Connect?

The relationship between these factors is important. GAD normally helps convert glutamate into GABA, one of the brain’s main inhibitory neurotransmitters. GABA acts like a braking system for nerve activity. When autoimmune processes interfere with GABA-related pathways, that braking effect can become weaker, allowing motor circuits to become unusually active.

GAD antibodies are therefore an important marker in SPS, but they do not explain every case. Some people with a clinical diagnosis of SPS do not have detectable GAD antibodies and may have other antibodies, including antibodies against glycine receptors or amphiphysin. This is one reason researchers consider SPS a spectrum of autoimmune neurological disorders rather than a condition caused by one antibody alone.

Several risk factors are associated with SPS, particularly having another autoimmune disease. Type 1 diabetes is one of the better-known associations. Still, having diabetes or another autoimmune disorder does not mean a person will develop SPS. The condition remains rare, and researchers continue to investigate why autoimmune activity targets neurological pathways in some people but not others.

What Are the Risk Factors and Triggers of SPS?

The risk factors and common triggers of SPS are listed below. Not every person with SPS has the same triggers, and a trigger can worsen symptoms without being the underlying cause of the disease.

• Autoimmune disease: Having another autoimmune condition may indicate immune-system susceptibility associated with developing SPS.
• Type 1 diabetes: Type 1 diabetes shares autoimmune mechanisms with SPS and occurs relatively often among people with GAD-antibody-associated disease.
• Emotional stress: Emotional stress can increase muscle activity and make stiffness or spasms more difficult to control.
• Sudden movement: Sudden or unexpected movement can activate exaggerated muscle responses and trigger painful spasms.
• Loud sounds: Unexpected loud sounds can produce an exaggerated startle response, followed by sudden muscle contraction or spasms.
• Cold temperatures: Cold temperatures may increase muscle stiffness and discomfort in some people, although individual responses vary.
• Physical contact: Unexpected touch or physical stimulation can activate spasms because inhibitory control of motor pathways is impaired.
• Emotional distress: Emotional distress may intensify existing symptoms by increasing nervous-system arousal and making spasms more frequent.

These triggers can have a significant impact on everyday living. Activities such as walking through crowded places, travelling, exercising, or responding to unexpected noises may become more difficult because the person cannot always predict when a spasm will occur.

How Does Stiff Person Syndrome Affect Daily Life?

The ways stiff-person syndrome affects adults are listed below. The effects depend on the severity, affected muscles, frequency of spasms, and response to treatment.

• Mobility: Persistent stiffness and spasms can make walking, climbing stairs, standing, and changing position physically demanding.
• Work: Reduced mobility, unpredictable spasms, and fatigue may make physically demanding or stressful work harder to maintain.
• Social activities: Fear of sudden spasms or falls can cause people to avoid crowded places, travel, or social events.
• In men: SPS may interfere with mobility, employment, exercise, and independence, depending on symptom severity rather than sex alone.
• In women: Women may experience the same neurological symptoms, with autoimmune conditions occurring alongside SPS in some patients.
• Relationship: Pain, reduced independence, anxiety, and restrictions on daily activities can place additional emotional and practical pressure on a relationship.
• Sleep: Muscle stiffness, painful spasms, and difficulty finding a comfortable position may interrupt sleep or make resting difficult.
• Falls: Sudden spasms and impaired balance can increase the risk of falls and related injuries.

How Is Stiff Person Syndrome Diagnosed?

The main ways to diagnose stiff-person syndrome are listed below. There is no single test that confirms every case, so neurologists combine clinical findings with laboratory and electrophysiological evidence.

• Neurological examination: A neurologist assesses muscle tone, reflexes, posture, movement, walking pattern, spasms, and responses to sensory stimulation.
• Blood testing: Blood tests can identify antibodies such as anti-GAD65 and other immune markers associated with SPS.
• Electromyography (EMG): EMG can detect continuous involuntary motor-unit activity, supporting the diagnosis when clinical symptoms suggest SPS.
• Clinical history: Doctors review symptom progression, spasm triggers, associated autoimmune diseases, medication history, and functional changes over time.
• Differential diagnosis: Clinicians exclude conditions such as ALS, multiple sclerosis, dystonia, Parkinson’s disease, tetanus, and functional neurological disorders.
• DSM-5 criteria: SPS is not diagnosed using DSM-5 criteria because it is a neurological autoimmune disorder rather than a psychiatric diagnosis.
• Imaging: MRI or other imaging may help exclude structural brain or spinal cord disorders that can produce similar neurological symptoms.
• Specialist assessment: A neurologist or specialist centre may combine examination, antibody results, EMG findings, and clinical history before reaching a diagnosis.

Diagnosis is therefore different from curing the condition. Testing establishes whether the symptoms fit SPS and helps identify other possible causes, while treatment focuses on controlling symptoms and, where appropriate, the underlying autoimmune activity.

Are There Any Cures for Stiff Person Syndrome?

No, there is no permanent cure for stiff-person syndrome because the autoimmune process responsible for the condition cannot currently be eliminated. SPS is a chronic neurological disorder, so treatment focuses on controlling abnormal muscle activity, reducing spasms and pain, and addressing the underlying immune dysfunction where appropriate.

With proper treatment, many people can achieve better symptom control and maintain greater independence. Treatment needs to be individualised because the severity, antibody profile, affected muscles, and response to medicines vary considerably between patients.

What Are the Treatments of Stiff Person Syndrome?

The treatment options of stiff-person syndrome involve medicines that reduce muscle overactivity, immune-based treatments, physical rehabilitation, and supportive therapies such as hydrotherapy.

The treatments of stiff-person syndrome are listed below. Doctors generally combine approaches according to the person’s symptoms, disease severity, underlying causes, antibody findings, and response to previous treatment. An evidence-based treatment plan can reduce spasms while also addressing the autoimmune component of SPS.

How Do These Treatments Help?

Muscle relaxants can reduce the excessive muscle activity responsible for stiffness and spasms. Baclofen, for example, activates GABA-B receptors and can reduce excitatory signalling within the spinal cord. A doctor may consider it when muscle rigidity remains troublesome despite other treatment.

Benzodiazepines, particularly diazepam, are commonly used to control SPS-related stiffness and spasms because they strengthen GABA-A receptor activity. This increases inhibitory signalling in the nervous system and can make involuntary contractions less frequent or severe. Because benzodiazepines can cause sedation, tolerance, dependence, and other adverse effects, their use requires careful medical supervision.

IVIG therapy works differently from muscle-relaxing medicines. The pooled antibodies appear to alter abnormal immune activity rather than simply suppressing muscle contractions. Clinical trials have shown that IVIG can improve stiffness, sensitivity to triggers, and physical functioning in some people with SPS.

Immunotherapy is directed towards the autoimmune component of the illness. Medicines such as rituximab reduce specific B-cell populations involved in antibody production. Its effectiveness varies between patients, so specialist neurologists and immunologists generally consider the potential benefits and risks before using it.

Physical therapy does not remove the autoimmune cause of SPS, but it can help preserve flexibility, strength, balance, and functional movement. Gentle, carefully supervised exercises may also reduce the physical consequences of prolonged stiffness. Exercise intensity needs to be adapted because excessive exertion or sudden movement can trigger spasms in some people.

Hydrotherapy provides a different environment for rehabilitation. Warm water can reduce the sensation of stiffness while buoyancy supports the body during movement. This may make stretching, balance exercises, and controlled walking easier for people whose symptoms make land-based exercise difficult.

Treatment is rarely about choosing one medicine or therapy in isolation. The best approach usually combines symptom control with rehabilitation and, where appropriate, treatment directed at the underlying causes of SPS. Because the condition is rare and treatments can carry significant risks, decisions should be made with a doctor experienced in neurological or autoimmune disorders.

Is Seeing a Doctor Necessary Before Taking Stiff Person Syndrome Medications?

Yes, seeing a doctor is necessary before taking stiff-person syndrome medications because SPS is a rare neurological disorder, and its medicines can have significant effects on the nervous system. Some treatments also require specialist monitoring because they can cause sedation, dependence, immune-related complications, or other adverse effects.

Medical supervision is important because SPS symptoms can resemble other neurological conditions, and the correct treatment depends on the person’s diagnosis, symptoms, antibody profile, other medical conditions, and current medicines. Medicines such as diazepam and baclofen can reduce muscle activity but may also cause drowsiness, impaired coordination, and other side effects.

Before prescribing treatment, a doctor may evaluate the severity and pattern of muscle stiffness and spasms, walking ability, neurological signs, previous treatments, autoimmune conditions, and laboratory findings. The doctor may also monitor blood tests, medication interactions, sedation, breathing, muscle function, and treatment response, depending on the medicine being used.

This assessment helps the clinician choose an appropriate dose and decide whether the treatment is providing enough benefit without creating unnecessary risks.

What Are the Best Medications for Stiff Person Syndrome?

The best medications for stiff-person syndrome include diazepam, baclofen, other muscle-relaxing medicines, and immune-directed treatments such as intravenous immunoglobulin (IVIG) when clinically appropriate.

The medications for stiff-person syndrome are listed below. There is no single medicine that works best for everyone. Treatment is selected according to symptoms, disease severity, underlying autoimmune activity, and the person’s response to previous therapies.

• Diazepam: Diazepam is a benzodiazepine that increases inhibitory GABA-A receptor activity in the central nervous system, helping reduce excessive muscle activity, rigidity, and painful spasms.
• Baclofen: Baclofen is a GABA-B receptor agonist that reduces excitatory signalling in the spinal cord, helping decrease muscle stiffness and involuntary spasms associated with SPS.
• Intravenous immunoglobulin (IVIG): IVIG is an immune-modifying treatment containing pooled antibodies from donors that can alter abnormal immune activity and improve SPS symptoms in some patients.
• Rituximab: Rituximab is a monoclonal antibody that reduces CD20-positive B cells involved in immune responses and may be considered for selected treatment-resistant SPS cases.

The choice between these medicines depends on the individual rather than a simple ranking. A neurologist may use a muscle-relaxing medicine for symptom control while considering immune-directed treatment when autoimmune activity is clinically significant.

How Does Diazepam Help Relieve the Symptoms of Stiff Person Syndrome?

Diazepam helps relieve the symptoms of stiff-person syndrome by enhancing the effects of GABA at the GABA-A receptor, strengthening inhibitory signalling that counteracts the reduced GABAergic inhibition associated with muscle stiffness and spasms.

GABA acts as an inhibitory chemical messenger in the central nervous system. It helps prevent nerve cells from becoming excessively active. Diazepam binds to specific sites on GABA-A receptors and makes these receptors more responsive to GABA. This increases inhibitory activity and can reduce the abnormal motor-neuron activity responsible for persistent muscle contraction.

For someone with SPS, this effect can make muscles less rigid and reduce the frequency or severity of painful spasms. Diazepam also has sedative and anticonvulsant properties, which may help reduce heightened nervous-system activity and some forms of anxiety associated with unpredictable spasms.

The medicine does not remove the autoimmune process that causes SPS. Its main role is symptom control. Because diazepam can cause drowsiness, impaired coordination, tolerance, and dependence, it should only be used under appropriate medical supervision and at a dose determined by a qualified prescriber.

What Are the Legal Ways to Buy Diazepam for SPS in the UK?

The legal ways to buy diazepam for stiff-person syndrome in the UK are listed below. Diazepam is a prescription-only medicine, so it cannot legally be supplied without a valid prescription.

• GP prescription: A GP can assess SPS symptoms and prescribe diazepam when clinically appropriate.
• Specialist prescription: A neurologist or other qualified specialist can prescribe diazepam following an appropriate medical assessment.
• NHS pharmacy: A valid NHS prescription can be dispensed by a registered UK pharmacy.
• Private prescription: A registered private prescriber can prescribe diazepam after assessing whether treatment is appropriate.
• Registered pharmacy: A legitimate pharmacy can supply prescribed diazepam after receiving and validating the prescription.
• Online pharmacy: A UK-registered online pharmacy may supply diazepam only after a lawful prescription and appropriate clinical checks.

Buying diazepam from unregulated websites, social-media sellers, or other unauthorised sources is not a legal or safe alternative to obtaining a prescription.

Is It Possible to Buy Diazepam for Stiff Person Syndrome in the UK Without a Prescription?

No, it is not possible to buy diazepam for stiff-person syndrome without a prescription in the UK because diazepam is a prescription-only medicine (POM) and is legally controlled. The NHS states that diazepam is available only with a prescription, while UK government records classify diazepam as a Class C, Schedule 4 Part 1 controlled drug.

This applies regardless of which type of stiff-person syndrome a person has or how severe their symptoms of stiff-person syndrome may be. A legitimate prescriber needs to assess the diagnosis, the SPS causes, other medicines, and the potential benefits and risks before prescribing diazepam. It is also important because diazepam can cause drowsiness, dependence, tolerance, and withdrawal symptoms, particularly with prolonged use.

There can be a narrow distinction between obtaining a new supply without a prescription and receiving an emergency supply of a previously prescribed medicine. Diazepam in the UK is only available in certain circumstances when specific legal requirements are met. This does not mean someone can simply walk into a shop and buy diazepam without medical authorisation.

A pharmacy may therefore be able to help in an emergency or special circumstance, but the pharmacist must follow the applicable legal requirements. For example, NHS guidance explains that emergency supplies can be considered when someone has run out of a medicine they normally take, while certain controlled drugs have additional restrictions.

For someone with suspected SPS, the safer approach is to obtain a proper diagnosis and discuss evidence-based stiff-person syndrome treatments with a neurologist or other qualified prescriber. Diazepam may be part of symptom management, but it does not treat the underlying autoimmune process. Other approaches can include muscle-relaxing medicines, immunotherapy, IVIG, and physical rehabilitation.

The same principle applies to stiff-man syndrome medications, which is an older name for medicines used to manage what is now generally called stiff-person syndrome. Unregulated websites or sellers offering diazepam without the required prescription are not an alternative to legitimate medical care. UK authorities have taken enforcement action against illegal online supply of prescription-only medicines and controlled drugs.